Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immunome (IMNM) EPS (Basic) (2023 - 2025)

Historic EPS (Basic) for Immunome (IMNM) over the last 3 years, with Q3 2025 value amounting to -$0.65.

  • Immunome's EPS (Basic) rose 1666.67% to -$0.65 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.95, marking a year-over-year increase of 6362.52%. This contributed to the annual value of -$5.21 for FY2024, which is 306.84% up from last year.
  • Latest data reveals that Immunome reported EPS (Basic) of -$0.65 as of Q3 2025, which was up 1666.67% from -$0.5 recorded in Q2 2025.
  • In the past 5 years, Immunome's EPS (Basic) registered a high of -$0.35 during Q1 2023, and its lowest value of -$4.22 during Q4 2023.
  • Its 3-year average for EPS (Basic) is -$1.12, with a median of -$0.6 in 2024.
  • Its EPS (Basic) has fluctuated over the past 5 years, first tumbled by 61714.29% in 2024, then surged by 7928.29% in 2025.
  • Over the past 3 years, Immunome's EPS (Basic) (Quarter) stood at -$4.22 in 2023, then skyrocketed by 66.47% to -$1.41 in 2024, then skyrocketed by 54.06% to -$0.65 in 2025.
  • Its last three reported values are -$0.65 in Q3 2025, -$0.5 for Q2 2025, and -$0.52 during Q1 2025.